Caribou Biosciences (CRBU)
(Delayed Data from NSDQ)
$2.49 USD
+0.05 (2.05%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $2.48 -0.01 (-0.40%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Balance Sheet
Fiscal Year End for Caribou Biosciences, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 329 | 248 | 376 | 16 | 0 |
Receivables | 2 | 2 | 7 | 4 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 8 | 10 | 9 | 5 | 0 |
Total Current Assets | 339 | 260 | 391 | 24 | 0 |
Net Property & Equipment | 18 | 11 | 5 | 4 | 0 |
Investments & Advances | 51 | 77 | 45 | 8 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 2 | 2 | 1 | 1 | 0 |
Total Assets | 432 | 374 | 442 | 36 | 0 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 3 | 1 | 4 | 3 | 0 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 21 | 16 | 13 | 9 | 0 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 3 | 10 | 9 | 1 | 0 |
Total Current Liabilities | 28 | 28 | 26 | 12 | 0 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 7 | 16 | 23 | 1 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 3 | 2 | 6 | 5 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 64 | 73 | 55 | 18 | 0 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 41 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 668 | 500 | 486 | 7 | 0 |
Retained Earnings | -299 | -197 | -98 | -31 | 0 |
Other Equity | 0 | -2 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 368 | 301 | 388 | 18 | 0 |
Total Liabilities & Shareholder's Equity | 432 | 374 | 442 | 36 | 0 |
Total Common Equity | 368 | 301 | 388 | -23 | 0 |
Shares Outstanding | 88.40 | 61.00 | 60.10 | NA | NA |
Book Value Per Share | 4.17 | 4.93 | 6.45 | 0.00 | 0.00 |
Fiscal Year End for Caribou Biosciences, Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 294 | 329 | 338 | 259 |
Receivables | NA | 3 | 2 | 3 | 2 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 0 | 0 | 0 | 0 |
Other Current Assets | NA | 8 | 8 | 9 | 7 |
Total Current Assets | NA | 305 | 339 | 351 | 269 |
Net Property & Equipment | NA | 19 | 18 | 17 | 15 |
Investments & Advances | NA | 60 | 51 | 66 | 41 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 0 | 0 | 0 | 0 |
Deposits & Other Assets | NA | 2 | 2 | 2 | 1 |
Total Assets | NA | 407 | 432 | 458 | 350 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 6 | 3 | 2 | 4 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 19 | 21 | 18 | 16 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 3 | 3 | 3 | 13 |
Total Current Liabilities | NA | 29 | 28 | 25 | 34 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 6 | 7 | 7 | 19 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 3 | 1 | 1 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 64 | 64 | 59 | 80 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 0 | 0 | 0 | 0 |
Capital Surplus | NA | 684 | 668 | 664 | 525 |
Retained Earnings | NA | -341 | -299 | -265 | -255 |
Other Equity | NA | 0 | 0 | -1 | -1 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | 343 | 368 | 398 | 269 |
Total Liabilities & Shareholder's Equity | NA | 407 | 432 | 458 | 350 |
Total Common Equity | 0 | 343 | 368 | 398 | 269 |
Shares Outstanding | 90.30 | 90.30 | 88.40 | 88.20 | 66.10 |
Book Value Per Share | 0.00 | 3.80 | 4.17 | 4.52 | 4.08 |